Your health insurance premiums keep climbing. But who’s really driving those costs? Massachusetts just became the first state to demand answers from a group that’s been operating in the shadows: private equity firms buying up hospitals and medical practices.
On November 12, 2025, the Massachusetts Health Policy Commission will hold a groundbreaking hearing that forces 16 new stakeholders to explain their role in the state’s healthcare market. For the first time, private equity firms, pharmacy benefit managers, and pharmaceutical manufacturers must submit sworn testimony about how their business models affect what you pay for care.
This isn’t your typical regulatory meeting. According to Goodwin Procter’s analysis, the January 2025 law expansion represents the most significant shift in healthcare cost oversight in a decade. All testimony submissions were due October 31, 2025, and are now publicly available—giving consumers unprecedented visibility into who profits from rising healthcare costs.
Why Private Equity Finally Faces Scrutiny
Private equity has quietly become a major force in American healthcare. Firms buy hospitals, physician practices, nursing homes, and ambulance companies—then restructure operations to maximize returns. Critics argue this financial engineering drives up costs while reducing care quality.
Massachusetts is calling their bluff.
The state’s updated healthcare transactions law now requires sworn testimony from entities that were never part of the conversation before:
- Private equity firms that own or invest in Massachusetts healthcare facilities, forcing disclosure of how ownership structures and financial strategies affect operating costs and patient billing.
- Real Estate Investment Trusts (REITs) that control hospital and medical office properties—a growing trend where facilities sell real estate then lease it back at higher rates, costs ultimately passed to patients and insurers.
- Pharmacy Benefit Managers (PBMs) like CVS Caremark and Express Scripts, the middlemen between insurers and drug manufacturers who negotiate prices but take significant cuts.
- Pharmaceutical manufacturers setting list prices that determine what insurers and patients pay.
- Management Services Organizations (MSOs) providing administrative services to practices, another layer of cost between doctors and patients.
Previously, Health Policy Commission hearings focused on hospitals and insurers. Now the spotlight hits financial actors operating behind the scenes.
What the November 12 Hearing Could Reveal About Your Premiums
The HPC selected 16 entities to provide pre-filed testimony by October 31. These submissions are now public record—meaning consumers, journalists, and policymakers can examine exactly how these companies describe their impact on Massachusetts healthcare costs.
Here’s what to watch for in the testimony:
| Stakeholder Type | Key Questions |
|---|---|
| Private Equity Firms | How many Massachusetts facilities do they own? What cost-cutting measures have been implemented? How do profit targets affect staffing and care delivery? |
| REITs | What percentage of facility operating costs goes to rent? How have lease rates changed post-acquisition? Impact on patient billing? |
| PBMs | What’s the spread between wholesale drug costs and amounts charged to insurers? How much do rebates actually reduce premiums? Why are patients paying more despite “negotiated discounts”? |
| Pharma Manufacturers | How are Massachusetts launch prices set? What’s the relationship between list prices and net prices after rebates? |
These aren’t polite suggestions. The testimony is sworn under oath, carrying legal consequences for misleading statements. That’s a critical difference from voluntary industry reports.
4 Ways This Hearing Could Lower Your Healthcare Costs
Transparency alone doesn’t reduce premiums. But Massachusetts has a track record of turning data into action. The Health Policy Commission has authority to recommend legislation, investigate specific transactions, and publicly name entities contributing to excessive cost growth.
Potential consumer benefits from the expanded oversight:
- Exposure of hidden markups: If testimony reveals PBMs are pocketing 30-40% of drug spending, legislators may cap spreads or require pass-through pricing that directly reduces premiums.
- Private equity deal scrutiny: Future healthcare acquisitions by PE firms could face approval requirements based on cost impact projections, preventing deals that historically spike prices 10-20% post-acquisition.
- REIT lease restrictions: Massachusetts could limit sale-leaseback arrangements that convert owned facilities into rental properties with escalating costs passed to patients.
- Public accountability: The simple act of requiring sworn public testimony creates reputational pressure—entities may self-regulate knowing their practices face annual review.
Consider what happened when Massachusetts first required price transparency from hospitals in 2013. Within three years, the rate of healthcare cost growth slowed from 4.5% annually to 2.9%—saving consumers billions in cumulative premium increases.
What Other States Are Watching (And Why This Matters Beyond Massachusetts)
Massachusetts operates as a healthcare policy laboratory. The state’s 2006 universal coverage law became the model for the Affordable Care Act. Now other states are studying this private equity oversight approach.
Oregon, California, and Washington have introduced similar legislation requiring financial disclosure from healthcare investors. But Massachusetts is first to implement sworn testimony requirements with public disclosure deadlines.
Why the national interest? Private equity owns an estimated 30% of for-profit hospitals nationwide, up from less than 5% in 2005, according to Kaiser Family Foundation research. PE-owned practices also control significant portions of emergency medicine, anesthesiology, and specialty care.
If Massachusetts can demonstrate that expanded oversight slows cost growth without harming care quality, expect a wave of copycat legislation. That means what happens in Boston on November 12 could eventually affect your premiums in Phoenix, Atlanta, or Minneapolis.
Can You Access the Testimony? (Yes, and Here’s How)
Unlike most regulatory proceedings buried in bureaucratic websites, Massachusetts made these submissions easily accessible. By law, all pre-filed testimony submitted by October 31 must be publicly posted.
To review the actual testimony:
- Visit the Massachusetts Health Policy Commission website
- Navigate to “Cost Trends Hearings” section
- Select “2025 Annual Hearing Materials”
- Download individual entity submissions or the complete package
Patient advocates and consumer groups are already analyzing the submissions for cost drivers that directly impact insurance premiums. Some key revelations so far: Several private equity firms acknowledge “operational efficiency improvements” that, when translated from corporate speak, mean staffing reductions and service consolidations that can affect wait times and access.
The November 12 Hearing: What to Expect
Pre-filed testimony is step one. The live hearing allows HPC commissioners to question entities under oath. Unlike written submissions crafted by legal teams, live testimony under cross-examination often reveals uncomfortable truths.
Past hearings have produced memorable moments: Hospital executives unable to justify executive compensation packages while claiming financial distress. Insurers caught contradicting their own data about administrative costs. PBMs giving evasive answers about rebate calculations.
This year’s hearing runs all day November 12, with sessions divided by stakeholder category. It’s live-streamed and archived for public viewing—though few consumers have time to watch hours of testimony.
What matters more than the hearing itself: The HPC’s post-hearing report, typically released 60-90 days later. That document synthesizes testimony, identifies cost drivers, and makes specific policy recommendations to the Massachusetts legislature.
Those recommendations have teeth. Previous HPC reports led to prior authorization reform, surprise billing protections, and insurance market changes that affected every resident’s coverage.
Frequently Asked Questions
Which private equity firms must testify at the Massachusetts health cost hearing?
The Health Policy Commission selected 16 new stakeholders from various categories including private equity firms, but specific company names haven’t been publicly disclosed in advance. All entities required to submit testimony by October 31, 2025, are now listed on the HPC website along with their submissions. The selection criteria focused on firms with significant Massachusetts healthcare market presence through hospital ownership, physician practice acquisitions, or healthcare facility investments.
How does private equity ownership increase my health insurance premiums?
Private equity firms typically acquire healthcare facilities using significant debt, then increase revenue to service that debt and generate returns for investors. Common strategies include raising prices for procedures, increasing patient volume through aggressive billing, reducing staff to cut costs, and converting owned facilities to leased properties with higher rent. Studies show PE-acquired hospitals raise prices 10-20% within two years of acquisition. Since insurers negotiate rates with these facilities, higher prices get passed to consumers through increased premiums and cost-sharing.
When will Massachusetts act on findings from the November 12 health cost hearing?
The Health Policy Commission typically releases its annual report 60-90 days after the hearing, likely in January or February 2026. That report will analyze testimony, identify specific cost drivers, and make policy recommendations to the Massachusetts legislature. Legislative action depends on committee assignments and political priorities, but past HPC recommendations have resulted in new laws within 6-18 months. Some changes—like increased scrutiny of future healthcare transactions—could happen faster through administrative action without requiring new legislation.
Can pharmacy benefit managers be regulated more strictly after this hearing?
Yes. PBMs have operated with minimal oversight despite controlling billions in drug spending. Massachusetts could implement several reforms based on hearing findings: requiring PBMs to disclose exact spreads between wholesale drug costs and insurer charges, mandating pass-through pricing that eliminates hidden markups, capping administrative fees, or requiring PBMs to register and report financial data annually. Some states have already implemented PBM reforms, and Massachusetts testimony could accelerate similar action. Consumer impact would be direct—every dollar of PBM markup removed translates to lower premiums and prescription costs.
Will other states copy Massachusetts’ private equity healthcare oversight?
Likely. Oregon, California, and Washington have already introduced legislation modeled on Massachusetts’ approach. The key factor is results—if Massachusetts can demonstrate that expanded oversight slows cost growth without reducing care quality or access, other states will fast-track similar laws. Massachusetts has a history as a healthcare policy incubator; the state’s 2006 insurance reform became the foundation for the Affordable Care Act. The November 12 hearing represents the first real test of this expanded oversight model, with policy experts nationwide watching outcomes closely.
Bottom Line: Transparency Is Step One
Massachusetts won’t solve healthcare costs overnight. But requiring private equity firms, PBMs, and pharmaceutical manufacturers to publicly defend their practices under oath changes the power dynamic.
For decades, these entities operated with minimal scrutiny while healthcare costs grew faster than inflation. The November 12 hearing represents a shift: Consumers, regulators, and policymakers finally get access to detailed financial data about who profits from rising premiums.
What happens next depends on whether Massachusetts has the political will to act on uncomfortable findings. The sworn testimony is public. The cost impact is measurable. The question is whether regulators will use this new transparency to actually constrain costs or simply generate reports while premiums keep climbing.
Either way, you can now read exactly what these companies say about their role in your healthcare costs. All 16 testimonies are online, searchable, and sworn under penalty of perjury. That’s more transparency than the healthcare industry has faced in decades.
Worth taking a look before your next premium renewal notice arrives.